Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant ...

Oncolytics Biotech's randomized REO 033 study for pelareorep in second-line RAS-mutant microsatellite-stable metastatic colorectal cancer has nearly all clinical sites activated, with accelerated patient enrollment and interim data expected by year-end 2026. FDA alignment supports an accelerated approval pathway based on objective response rate and full approval on progression-free survival, advancing the drug's regulatory prospects.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 28 Sep 2026 and 29 Sep 2026.